Skip to content
Tablet Allopathic

Ornopain 8 mg tablet

Generic: Lornoxicam

Company: Incepta Pharmaceuticals Ltd.. Prices are as listed on BestinMeds; your pharmacy price may differ.

Strength8 mg
PackStrip: 250.00 taka

Reviewed by: not listed yet. Source: not listed yet.

Last updated April 13, 2026.

Compare

Same generic, same strength

Sorted by price per tablet. Ask your pharmacist before you switch brands.

Lornoxicam 8 mg tablets

Prices as listed on BestinMeds.

2 brands listed
Loricam18.00 taka per tablet
Ornopain (this medicine)25.00 taka per tablet

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250
Medicine guide

About this medicine

What this medicine is for, how to take it, and what to watch for.

Read the full Lornoxicam guide

Indications

Mild to moderate pain Short-term relief of acute mild to moderate pain Symptomatic relief of pain and inflammation in osteoarthritis Symptomatic relief of pain and inflammation in rheumatoid arthritis.

Dosage and administration

For all patients, the appropriate dosing regimen should be based upon individual response to treatment. Pain: 8-16 mg lornoxicam daily divided into 2 or 3 doses. The Maximum recommended daily dose is 16 mg. Osteoarthritis and Rheumatoid arthritis: Initial recommended dose is 12 mg lornoxicam daily divided into 2 or 3 doses. The maintenance dose should not exceed 16 mg lornoxicam daily. Lornoxicam film-coated tablets are supplied for oral use and should be taken with a sufficient quantity of liquid. Children and adolescents: Lornoxicam is not recommended for use in children and adolescents below age 18 due to a lack of data on safety and efficacy. Elderly: No special dosage modification is required for elderly patients above age 65, but Lornoxicam should be administered with precaution as gastrointestinal adverse effects are less well tolerated in this group. Renal impairment: For patients with mild to moderate renal impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses. Hepatic impairment: For patients with moderate hepatic impairment the maximum recommended daily dose is 12 mg divided in 2 or 3 doses.

Side effects

This information is not available. Ask your doctor or pharmacist.

Precautions and warnings

Renal impairment: Lornoxicam should be administered with precaution in patients with mild (serum creatinine 150-300 µmol/l) to moderate (serum creatinine 300 – 700 µmol/l) renal impairment due to dependency on renal prostaglandins for maintenance of renal blood flow. Treatment with lornoxicam should be discontinued if renal function deteriorates during treatment. Renal functions should be monitored in patients who undergo major surgery, with cardiac failure, receiving treatment with diuretics, receiving concomitant treatment with drugs that are suspected to or known to be able to cause kidney damage. Patients with blood coagulation disorders: Careful clinical monitoring and laboratory assessment is recommended (e.g. APTT). Hepatic impairment (e.g. liver cirrhosis): Clinical monitoring and laboratory assessments at regular intervals should be considered in patients with hepatic impairment as accumulation of lornoxicam (increase in AUC) may occur after treatment with daily doses of 12-16 mg. Apart from that, hepatic impairment does not seem to affect pharmacokinetic parameters of lornoxicam as compared to healthy subjects. Long term treatment (longer than 3 months): Regular laboratory assessments of haematology (haemoglobin), renal functions (creatinine) and liver enzymes are recommended. Elderly patients above 65 years: Monitoring of renal and hepatic function is recommended. Precaution is advised in elderly postoperative patients.

Pregnancy and lactation

Lornoxicam is contraindicated on the third trimester of pregnancy and should not be used during pregnancy in the first and second trimesters and delivery, as no clinical data on exposed pregnancies are available. There are no adequate data from the use of lornoxicam in pregnant women. Studies in animals have shown reproductive toxicity. There are no data on the excretion of lornoxicam in human breast milk. Lornoxicam is excreted in milk of lactating rats in relatively high concentrations. Therefore lornoxicam should not be used in breastfeeding women.

Clinical details

BestinMeds shares medicine information to help you compare. It does not replace advice from your doctor or pharmacist.

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250

Advertisement

Google Ads 970 x 250
Google Ads 300 x 250